InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway

Benzinga_recent_news01-09

InflaRx N.V. (NASDAQ:IFRX) on thursday said it is taking decisive steps to cut costs, streamline operations, and extend its cash runway as it sharpens its focus on izicopan, its lead investigational ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602734391?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/08/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-09 01:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602734391","market":"sh","top_or_hot":-1,"title":"InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway","media":"Benzinga_recent_news","content":"<div>\n<p>InflaRx N.V. (NASDAQ:IFRX) on thursday said it is taking decisive steps to cut costs, streamline operations, and extend its cash runway as it sharpens its focus on izicopan, its lead investigational ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/01/49791962/inflarx-plans-workforce-reduction-targets-mid-2027-cash-runway\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 01:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/01/49791962/inflarx-plans-workforce-reduction-targets-mid-2027-cash-runway><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>InflaRx N.V. (NASDAQ:IFRX) on thursday said it is taking decisive steps to cut costs, streamline operations, and extend its cash runway as it sharpens its focus on izicopan, its lead investigational ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/01/49791962/inflarx-plans-workforce-reduction-targets-mid-2027-cash-runway\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDS","symbol_name":"Aridis制药","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/01/49791962/inflarx-plans-workforce-reduction-targets-mid-2027-cash-runway","article_id":"2602734391","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/08/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49791962/inflarx-plans-workforce-reduction-targets-mid-2027-cash-runway","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602734391","pubTimestamp":1767892920,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"InflaRx outlines restructuring plans, workforce cuts, and reduced Gohibic spending to extend cash runway and focus development efforts on izicopan through mid-2027.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARDS":"Aridis制药","BK4139":"生物科技","IFRX":"InflaRx N.V."},"translate_title":"InflaRx计划裁员，目标是2027年中期现金跑道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IFRX":1,"ARDS":1},"content_text":"InflaRx N.V. (NASDAQ:IFRX) on thursday said it is taking decisive steps to cut costs, streamline operations, and extend its cash runway as it sharpens its focus on izicopan, its lead investigational asset, while significantly scaling back spending tied to Gohibic (vilobelimab).\nGohibic is a medicine used to treat acute respiratory distress syndrome due to COVID-19 infection.\nThe company said the changes are intended to improve capital efficiency and support further development of izicopan across hidradenitis suppurativa (HS) and other inflammatory and immunology (I&I) indications.\nAs part of the restructuring, InflaRx is reducing its workforce by about 30% and largely discontinuing non-essential activities outside izicopan development.\nThe company is also making substantial cuts to Gohibic-related commercial spending and support functions, reflecting a strategic shift away from broad commercialization efforts.\nInflaRx expects the restructuring to result in a one-time charge of roughly $7 million.\nFollowing the restructuring, the company anticipates a significantly leaner cost base and said it now expects its cash runway to extend into mid-2027.\nDespite the pullback in spending, InflaRx said it will continue to support the ongoing BARDA-sponsored \"Just Breathe\" Phase 2 platform study evaluating Gohibic in acute respiratory distress syndrome (ARDS), and does not expect the changes to affect the trial.\nGohibic will remain available for ordering in the U.S. under its emergency use authorization, with InflaRx maintaining the ability to meet demand on a reactive basis.\nThe company also said it continues to evaluate partnering opportunities for Gohibic in both the U.S. and Europe and plans to engage with the FDA on a potential development path for vilobelimab in pyoderma gangrenosum, likely with a partner.\nLooking ahead, InflaRx is prioritizing izicopan, citing data that suggest favorable pharmacokinetics and pharmacodynamics, as well as differentiation within the C5a/C5aR pathway.\nThe company said it is advancing toward Phase 2b readiness in HS and remains in discussions with the FDA on study design and endpoints.\nBeyond HS, InflaRx sees an opportunity for izicopan in chronic spontaneous urticaria (CSU) and other I&I indications.\nThe company recently closed a low-enrolling anti-IgE–refractory CSU cohort and plans to use existing Phase 2a data to guide next steps, with updates expected later this year.\nIFRX Price Action: InflaRx shares were down 5.00% at $1.13 at the time of publication on Thursday, according to Benzinga Pro data.\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602734391","isCrawlerRequest":true}